Finoriq research workspace
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Company Overview
MADRIGAL PHARMACEUTICALS, INC. offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist. Review MDGL filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Company
- MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Ticker
- MDGL
- Market Cap
- $12.4B
- Latest Price
- $536.86
- Industry
- Biotech & Pharma
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Current Valuation Metrics
Static valuation preview for MADRIGAL PHARMACEUTICALS, INC. (MDGL). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 11.4x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -2.4% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -2.1% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 23.8x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.